ciprofloxacin has been researched along with mbx 1090 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bavari, S; Bowlin, T; Butler, MM; Gussio, R; Houseweart, C; Lane, D; Moir, DT; Nguyen, T; Opperman, T; Panchal, RG; Peet, NP; Ulrich, RL; Williams, JD | 1 |
| Bavari, S; Bowlin, TL; Houseweart, C; Moir, DT; Opperman, TJ; Panchal, RG; Peet, NP; Williams, JD | 1 |
2 other study(ies) available for ciprofloxacin and mbx 1090
| Article | Year |
|---|---|
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
Topics: Animals; Anti-Bacterial Agents; Bacillus anthracis; Cell Death; Cell Line; Gram-Negative Bacteria; Gram-Positive Bacteria; Macrophages; Mice; Staphylococcus aureus; Yersinia pestis | 2009 |
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Indoles; Microbial Sensitivity Tests; Mutation; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcus aureus; Structure-Activity Relationship; Substrate Specificity | 2010 |